| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.822 | 0.004 | 0.822 | Hypolipemic | 0.417 0.022 DBMET00521 | ||
| 0.76 | 0.004 | 0.76 | Vasodilator, peripheral | 0.319 0.087 DBMET00513 0.659 0.009 DBMET00521 | ||
| 0.679 | 0.005 | 0.679 | Cardiotonic | 0.299 0.057 DBMET00521 | ||
| 0.668 | 0.01 | 0.754 | Cholesterol antagonist | 0.337 0.07 DBMET00513 0.754 0.005 DBMET00521 | DBMET00521 | |
| 0.59 | 0.006 | 0.59 | Vasodilator | 0.442 0.017 DBMET00521 | ||
| 0.588 | 0.006 | 0.588 | Psychostimulant | 0.248 0.059 DBMET00513 0.533 0.009 DBMET00521 | ||
| 0.592 | 0.014 | 0.67 | Spasmolytic | 0.225 0.103 DBMET00513 0.67 0.008 DBMET00521 | DBMET00521 | |
| 0.604 | 0.027 | 0.604 | Cyclophilin D inhibitor | 0.402 0.09 DBMET00521 | ||
| 0.592 | 0.02 | 0.592 | Aldehyde oxidase inhibitor | 0.544 0.027 DBMET00513 0.56 0.024 DBMET00521 | ||
| 0.557 | 0.006 | 0.674 | Platelet aggregation inhibitor | 0.674 0.005 DBMET00521 | DBMET00521 | |
| 0.534 | 0.005 | 0.534 | Alpha-N-acetylglucosaminidase inhibitor | 0.5 0.005 DBMET00513 0.462 0.006 DBMET00521 | ||
| 0.533 | 0.006 | 0.533 | Hepatoprotectant | 0.334 0.022 DBMET00521 | ||
| 0.532 | 0.025 | 0.628 | Antithrombotic | 0.195 0.184 DBMET00513 0.628 0.013 DBMET00521 | DBMET00521 | |
| 0.498 | 0.015 | 0.498 | Hypoglycemic | 0.3 0.053 DBMET00521 | ||
| 0.475 | 0.019 | 0.475 | Vasodilator, coronary | 0.315 0.076 DBMET00513 0.433 0.026 DBMET00521 | ||
| 0.484 | 0.045 | 0.484 | Antibacterial | 0.457 0.054 DBMET00521 | ||
| 0.436 | 0.005 | 0.436 | Insulin secretagoues | 0.25 0.019 DBMET00521 | ||
| 0.448 | 0.037 | 0.516 | 5 Hydroxytryptamine release stimulant | 0.516 0.025 DBMET00513 0.272 0.079 DBMET00521 | DBMET00513 | |
| 0.408 | 0.007 | 0.456 | Interleukin 6 antagonist | 0.456 0.005 DBMET00521 | DBMET00521 | |
| 0.397 | 0.01 | 0.422 | Cholinergic | 0.422 0.009 DBMET00521 | DBMET00521 | |
| 0.392 | 0.005 | 0.761 | GABA C receptor agonist | 0.391 0.005 DBMET00513 0.761 0.002 DBMET00521 | DBMET00521 | |
| 0.396 | 0.011 | 0.659 | Phospholipase C inhibitor | 0.189 0.052 DBMET00513 0.659 0.003 DBMET00521 | DBMET00521 | |
| 0.421 | 0.044 | 0.421 | Immunostimulant | 0.211 0.114 DBMET00513 0.401 0.049 DBMET00521 | ||
| 0.401 | 0.035 | 0.401 | Antioxidant | 0.284 0.068 DBMET00521 | ||
| 0.387 | 0.042 | 0.387 | Nootropic | |||
| 0.374 | 0.033 | 0.594 | Platelet antagonist | 0.594 0.007 DBMET00521 | DBMET00521 | |
| 0.382 | 0.071 | 0.382 | Immunosuppressant | 0.313 0.107 DBMET00521 | ||
| 0.31 | 0.005 | 0.399 | Glutamate dehydrogenase inhibitor | 0.179 0.012 DBMET00513 0.399 0.004 DBMET00521 | DBMET00521 | |
| 0.331 | 0.031 | 0.369 | Peroxidase inhibitor | 0.369 0.025 DBMET00513 0.277 0.042 DBMET00521 | DBMET00513 | |
| 0.321 | 0.035 | 0.465 | 5 Hydroxytryptamine uptake stimulant | 0.384 0.017 DBMET00513 0.465 0.006 DBMET00521 | DBMET00521 | |
| 0.295 | 0.014 | 0.362 | Phospholipase A2 inhibitor | 0.362 0.007 DBMET00521 | DBMET00521 | |
| 0.328 | 0.047 | 0.476 | DNA damaging | 0.476 0.016 DBMET00513 0.354 0.04 DBMET00521 | DBMET00513 | |
| 0.37 | 0.099 | 0.419 | 5 Hydroxytryptamine release inhibitor | 0.419 0.067 DBMET00513 0.336 0.128 DBMET00521 | DBMET00513 | |
| 0.353 | 0.084 | 0.565 | GABA C receptor rho-3 antagonist | 0.565 0.012 DBMET00513 0.481 0.031 DBMET00521 | DBMET00513 | |
| 0.332 | 0.065 | 0.515 | Apoptosis antagonist | 0.515 0.018 DBMET00521 | DBMET00521 | |
| 0.306 | 0.046 | 0.381 | Interleukin antagonist | 0.381 0.034 DBMET00521 | DBMET00521 | |
| 0.265 | 0.007 | 0.294 | Phosphofructokinase-1 inhibitor | 0.195 0.012 DBMET00513 0.294 0.005 DBMET00521 | DBMET00521 | |
| 0.379 | 0.124 | 0.518 | Caspase 9 stimulant | 0.471 0.072 DBMET00513 0.518 0.053 DBMET00521 | DBMET00521 | |
| 0.318 | 0.063 | 0.401 | Sodium/bile acid cotransporter inhibitor | 0.401 0.017 DBMET00521 | DBMET00521 | |
| 0.25 | 0.003 | 0.25 | Acetylcholine M3 receptor agonist | 0.226 0.003 DBMET00521 | ||
| 0.319 | 0.072 | 0.384 | Immunomodulator | 0.384 0.049 DBMET00521 | DBMET00521 | |
| 0.258 | 0.012 | 0.258 | Interleukin 4 antagonist | |||
| 0.286 | 0.041 | 0.411 | Tyrosine 3 hydroxylase inhibitor | 0.376 0.011 DBMET00513 0.411 0.007 DBMET00521 | DBMET00521 | |
| 0.247 | 0.005 | 0.272 | Carbamoyl phosphate synthetase inhibitor | 0.154 0.011 DBMET00513 0.272 0.005 DBMET00521 | DBMET00521 | |
| 0.26 | 0.019 | 0.352 | Succinate dehydrogenase inhibitor | 0.277 0.015 DBMET00513 0.352 0.005 DBMET00521 | DBMET00521 | |
| 0.249 | 0.01 | 0.335 | Adenylate kinase inhibitor | 0.255 0.01 DBMET00513 0.335 0.005 DBMET00521 | DBMET00521 | |
| 0.243 | 0.007 | 0.371 | Triose-phosphate isomerase inhibitor | 0.245 0.007 DBMET00513 0.371 0.004 DBMET00521 | DBMET00521 | |
| 0.254 | 0.02 | 0.274 | Acetylcholinesterase inhibitor | 0.274 0.016 DBMET00521 | DBMET00521 | |
| 0.248 | 0.014 | 0.389 | Ferrochelatase inhibitor | 0.33 0.005 DBMET00513 0.389 0.004 DBMET00521 | DBMET00521 | |
| 0.338 | 0.105 | 0.447 | Histamine release inhibitor | 0.39 0.081 DBMET00513 0.447 0.051 DBMET00521 | DBMET00521 | |
| 0.241 | 0.013 | 0.241 | Antibacterial (Helicobacter pylori) | 0.116 0.088 DBMET00513 0.163 0.037 DBMET00521 | ||
| 0.231 | 0.005 | 0.231 | Alcohol oxidase inhibitor | 0.221 0.005 DBMET00513 0.188 0.007 DBMET00521 | ||
| 0.28 | 0.057 | 0.427 | Angiogenesis stimulant | 0.427 0.018 DBMET00521 | DBMET00521 | |
| 0.24 | 0.018 | 0.289 | Cell wall synthesis inhibitor | 0.195 0.032 DBMET00513 0.289 0.01 DBMET00521 | DBMET00521 | |
| 0.243 | 0.022 | 0.281 | Cholinergic antagonist | 0.1 0.095 DBMET00513 0.281 0.016 DBMET00521 | DBMET00521 | |
| 0.279 | 0.059 | 0.337 | Interleukin agonist | 0.269 0.066 DBMET00513 0.337 0.033 DBMET00521 | DBMET00521 | |
| 0.273 | 0.055 | 0.348 | Gastrin inhibitor | 0.278 0.051 DBMET00513 0.348 0.011 DBMET00521 | DBMET00521 | |
| 0.245 | 0.026 | 0.291 | Acetylcholine M1 receptor antagonist | 0.148 0.076 DBMET00513 0.291 0.016 DBMET00521 | DBMET00521 | |
| 0.221 | 0.005 | 0.3 | Glutamate decarboxylase inhibitor | 0.142 0.015 DBMET00513 0.3 0.004 DBMET00521 | DBMET00521 | |
| 0.237 | 0.023 | 0.281 | Anesthetic local | 0.109 0.075 DBMET00513 0.281 0.015 DBMET00521 | DBMET00521 | |
| 0.248 | 0.036 | 0.248 | Insulin sensitizer | 0.167 0.111 DBMET00513 0.237 0.042 DBMET00521 | ||
| 0.257 | 0.046 | 0.299 | Peptidyltransferase inhibitor | 0.173 0.141 DBMET00513 0.299 0.025 DBMET00521 | DBMET00521 | |
| 0.234 | 0.023 | 0.268 | Acetylcholine antagonist | 0.268 0.017 DBMET00521 | DBMET00521 | |
| 0.237 | 0.033 | 0.237 | Cytidine deaminase inhibitor | 0.151 0.075 DBMET00513 0.23 0.035 DBMET00521 | ||
| 0.211 | 0.008 | 0.211 | Sphingomyelinase inhibitor | 0.133 0.033 DBMET00513 0.174 0.016 DBMET00521 | ||
| 0.222 | 0.021 | 0.319 | Alkylator | 0.319 0.011 DBMET00513 0.31 0.012 DBMET00521 | DBMET00513 | |
| 0.201 | 0.005 | 0.201 | Acyl-CoA dehydrogenase inhibitor | 0.178 0.007 DBMET00513 0.179 0.007 DBMET00521 | ||
| 0.191 | 0.004 | 0.191 | Acetylcholine M2 receptor agonist | 0.185 0.004 DBMET00521 | ||
| 0.196 | 0.014 | 0.23 | GABA C receptor antagonist | 0.23 0.008 DBMET00513 0.229 0.008 DBMET00521 | DBMET00513 | |
| 0.248 | 0.068 | 0.349 | DNA synthesis inhibitor | 0.349 0.03 DBMET00513 0.315 0.039 DBMET00521 | DBMET00513 | |
| 0.185 | 0.006 | 0.217 | Glycine transporter 2 inhibitor | 0.217 0.005 DBMET00521 | DBMET00521 | |
| 0.189 | 0.015 | 0.231 | Vanilloid 1 agonist | 0.131 0.064 DBMET00513 0.231 0.007 DBMET00521 | DBMET00521 | |
| 0.188 | 0.014 | 0.22 | Acetylcholine nicotinic antagonist | 0.083 0.052 DBMET00513 0.22 0.011 DBMET00521 | DBMET00521 | |
| 0.178 | 0.012 | 0.203 | GABA C receptor rho-1 antagonist | 0.203 0.008 DBMET00513 0.201 0.008 DBMET00521 | DBMET00513 | |
| 0.183 | 0.018 | 0.206 | Catalase inhibitor | 0.113 0.035 DBMET00513 0.206 0.014 DBMET00521 | DBMET00521 | |
| 0.175 | 0.011 | 0.175 | Toll-Like receptor 4 antagonist | 0.106 0.06 DBMET00521 | ||
| 0.222 | 0.058 | 0.283 | Nitric-oxide synthase stimulant | 0.283 0.016 DBMET00513 0.191 0.104 DBMET00521 | DBMET00513 | |
| 0.216 | 0.055 | 0.216 | P-glycoprotein inhibitor | |||
| 0.185 | 0.025 | 0.219 | Aminopeptidase B inhibitor | 0.17 0.03 DBMET00513 0.219 0.017 DBMET00521 | DBMET00521 | |
| 0.174 | 0.013 | 0.183 | NADH dehydrogenase inhibitor | 0.183 0.012 DBMET00513 0.176 0.013 DBMET00521 | DBMET00513 | |
| 0.168 | 0.009 | 0.18 | Phenylalanine 4-hydroxylase inhibitor | 0.121 0.018 DBMET00513 0.18 0.008 DBMET00521 | DBMET00521 | |
| 0.158 | 0.001 | 0.158 | HMG CoA reductase inhibitor | 0.035 0.023 DBMET00521 | ||
| 0.18 | 0.025 | 0.216 | Adenylate cyclase stimulant | 0.183 0.024 DBMET00513 0.216 0.008 DBMET00521 | DBMET00521 | |
| 0.166 | 0.011 | 0.168 | Anabolic | 0.14 0.024 DBMET00513 0.168 0.01 DBMET00521 | DBMET00521 | |
| 0.261 | 0.107 | 0.412 | Interleukin 2 agonist | 0.412 0.024 DBMET00521 | DBMET00521 | |
| 0.312 | 0.164 | 0.375 | Apoptosis agonist | 0.375 0.126 DBMET00521 | DBMET00521 | |
| 0.165 | 0.018 | 0.18 | Ca2+-transporting ATPase inhibitor | 0.18 0.007 DBMET00513 0.176 0.009 DBMET00521 | DBMET00513 | |
| 0.177 | 0.031 | 0.276 | Adenylate cyclase inhibitor | 0.099 0.085 DBMET00513 0.276 0.016 DBMET00521 | DBMET00521 | |
| 0.177 | 0.031 | 0.245 | Acetylcholine muscarinic antagonist | 0.106 0.083 DBMET00513 0.245 0.015 DBMET00521 | DBMET00521 | |
| 0.147 | 0.004 | 0.217 | Aconitate hydratase inhibitor | 0.104 0.008 DBMET00513 0.217 0.003 DBMET00521 | DBMET00521 | |
| 0.187 | 0.044 | 0.191 | Thiol protease inhibitor | 0.125 0.107 DBMET00513 0.191 0.043 DBMET00521 | DBMET00521 | |
| 0.161 | 0.019 | 0.627 | Telomerase inhibitor | 0.627 0.004 DBMET00513 0.366 0.005 DBMET00521 | DBMET00513 | |
| 0.189 | 0.047 | 0.199 | ATPase inhibitor | 0.174 0.065 DBMET00513 0.199 0.038 DBMET00521 | DBMET00521 | |
| 0.183 | 0.041 | 0.183 | Interleukin 1 antagonist | 0.148 0.059 DBMET00521 | ||
| 0.152 | 0.012 | 0.157 | Aminopeptidase I inhibitor | 0.108 0.024 DBMET00513 0.157 0.011 DBMET00521 | DBMET00521 | |
| 0.206 | 0.067 | 0.286 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.286 0.028 DBMET00513 0.243 0.046 DBMET00521 | DBMET00513 | |
| 0.185 | 0.048 | 0.216 | Arachidonic acid antagonist | 0.209 0.025 DBMET00513 0.216 0.02 DBMET00521 | DBMET00521 | |
| 0.149 | 0.012 | 0.149 | Antimetabolite | 0.129 0.013 DBMET00521 | ||
| 0.16 | 0.024 | 0.233 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.233 0.011 DBMET00513 0.231 0.012 DBMET00521 | DBMET00513 | |
| 0.146 | 0.011 | 0.287 | Interferon agonist | 0.087 0.042 DBMET00513 0.287 0.004 DBMET00521 | DBMET00521 | |
| 0.158 | 0.026 | 0.281 | UDP-glucose 4-epimerase inhibitor | 0.281 0.011 DBMET00513 0.118 0.045 DBMET00521 | DBMET00513 | |
| 0.141 | 0.01 | 0.171 | Biliverdin reductase inhibitor | 0.171 0.008 DBMET00513 0.165 0.008 DBMET00521 | DBMET00513 | |
| 0.235 | 0.111 | 0.362 | Insulysin inhibitor | 0.276 0.074 DBMET00513 0.362 0.03 DBMET00521 | DBMET00521 | |
| 0.177 | 0.054 | 0.304 | Neurotensin receptor agonist | 0.177 0.053 DBMET00513 0.304 0.014 DBMET00521 | DBMET00521 | |
| 0.162 | 0.039 | 0.162 | Cholesterol synthesis inhibitor | 0.122 0.064 DBMET00513 0.156 0.042 DBMET00521 | ||
| 0.125 | 0.003 | 0.125 | Glucose-6-phosphate isomerase inhibitor | 0.093 0.006 DBMET00513 0.125 0.003 DBMET00521 | ||
| 0.152 | 0.031 | 0.182 | Mucolytic | 0.128 0.047 DBMET00513 0.182 0.018 DBMET00521 | DBMET00521 | |
| 0.126 | 0.015 | 0.144 | Bile acid receptor antagonist | 0.094 0.064 DBMET00513 0.144 0.009 DBMET00521 | DBMET00521 | |
| 0.153 | 0.044 | 0.177 | Cathepsin H inhibitor | 0.166 0.036 DBMET00513 0.177 0.03 DBMET00521 | DBMET00521 | |
| 0.113 | 0.009 | 0.152 | GABA B receptor agonist | 0.1 0.017 DBMET00513 0.152 0.004 DBMET00521 | DBMET00521 | |
| 0.115 | 0.013 | 0.143 | Ornithine carbamoyltransferase inhibitor | 0.09 0.018 DBMET00513 0.143 0.01 DBMET00521 | DBMET00521 | |
| 0.147 | 0.046 | 0.147 | Platelet activating factor antagonist | 0.109 0.071 DBMET00521 | ||
| 0.306 | 0.205 | 0.523 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.523 0.024 DBMET00513 0.342 0.16 DBMET00521 | DBMET00513 | |
| 0.122 | 0.021 | 0.138 | Glutamate release inhibitor | 0.135 0.014 DBMET00513 0.138 0.013 DBMET00521 | DBMET00521 | |
| 0.13 | 0.029 | 0.182 | Electrolyte absorption antagonist | 0.142 0.023 DBMET00513 0.182 0.011 DBMET00521 | DBMET00521 | |
| 0.104 | 0.005 | 0.161 | Fumarate hydratase inhibitor | 0.072 0.008 DBMET00513 0.161 0.004 DBMET00521 | DBMET00521 | |
| 0.139 | 0.04 | 0.18 | Expectorant | 0.1 0.069 DBMET00513 0.18 0.025 DBMET00521 | DBMET00521 | |
| 0.106 | 0.009 | 0.106 | Prostaglandin F2 alpha antagonist | 0.104 0.01 DBMET00521 | ||
| 0.107 | 0.011 | 0.156 | Phospholipase D inhibitor | 0.09 0.022 DBMET00513 0.156 0.003 DBMET00521 | DBMET00521 | |
| 0.123 | 0.027 | 0.419 | Porphobilinogen synthase inhibitor | 0.223 0.01 DBMET00513 0.419 0.004 DBMET00521 | DBMET00521 | |
| 0.162 | 0.067 | 0.18 | Diuretic | 0.18 0.053 DBMET00521 | DBMET00521 | |
| 0.135 | 0.043 | 0.174 | TRPA1 agonist | 0.122 0.056 DBMET00513 0.174 0.018 DBMET00521 | DBMET00521 | |
| 0.143 | 0.051 | 0.153 | Sphingosine 1-phosphate receptor 2 antagonist | 0.142 0.053 DBMET00513 0.153 0.037 DBMET00521 | DBMET00521 | |
| 0.095 | 0.004 | 0.095 | Geranyltranstransferase inhibitor | 0.058 0.015 DBMET00513 0.084 0.004 DBMET00521 | ||
| 0.114 | 0.024 | 0.114 | ATPase (Vacuolar H+) inhibitor | 0.111 0.027 DBMET00521 | ||
| 0.203 | 0.114 | 0.319 | Superoxide dismutase inhibitor | 0.319 0.044 DBMET00513 0.284 0.056 DBMET00521 | DBMET00513 | |
| 0.11 | 0.023 | 0.113 | Peroxisome proliferator-activated receptor gamma agonist | 0.113 0.022 DBMET00521 | DBMET00521 | |
| 0.104 | 0.018 | 0.104 | Ribonucleoside-diphosphate reductase inhibitor | 0.093 0.021 DBMET00521 | ||
| 0.104 | 0.02 | 0.125 | Estrogen-related receptor beta agonist | 0.116 0.012 DBMET00513 0.125 0.008 DBMET00521 | DBMET00521 | |
| 0.103 | 0.02 | 0.103 | Ribonucleotide reductase inhibitor | 0.095 0.022 DBMET00521 | ||
| 0.111 | 0.028 | 0.142 | Histidine decarboxylase inhibitor | 0.142 0.021 DBMET00513 0.123 0.025 DBMET00521 | DBMET00513 | |
| 0.12 | 0.038 | 0.213 | Prolactin inhibitor | 0.162 0.018 DBMET00513 0.213 0.007 DBMET00521 | DBMET00521 | |
| 0.085 | 0.004 | 0.085 | Carnitine palmitoyltransferase 1A inhibitor | 0.051 0.007 DBMET00521 | ||
| 0.173 | 0.092 | 0.324 | Anesthetic general | 0.274 0.041 DBMET00513 0.324 0.028 DBMET00521 | DBMET00521 | |
| 0.098 | 0.017 | 0.098 | Acetylcholine muscarinic agonist | 0.071 0.026 DBMET00513 0.069 0.027 DBMET00521 | ||
| 0.124 | 0.044 | 0.124 | Protease inhibitor | |||
| 0.151 | 0.072 | 0.254 | GABA C receptor rho-2 antagonist | 0.254 0.011 DBMET00513 0.204 0.027 DBMET00521 | DBMET00513 | |
| 0.106 | 0.027 | 0.131 | Vanilloid agonist | 0.131 0.014 DBMET00521 | DBMET00521 | |
| 0.084 | 0.006 | 0.088 | Carnitine palmitoyltransferase 1B inhibitor | 0.088 0.005 DBMET00521 | DBMET00521 | |
| 0.128 | 0.052 | 0.254 | Interleukin 8 antagonist | 0.117 0.066 DBMET00513 0.254 0.005 DBMET00521 | DBMET00521 | |
| 0.085 | 0.009 | 0.086 | Alpha-mannosidase inhibitor | 0.082 0.01 DBMET00513 0.086 0.009 DBMET00521 | DBMET00521 | |
| 0.08 | 0.005 | 0.15 | Membrane dipeptidase inhibitor | 0.047 0.018 DBMET00513 0.15 0.002 DBMET00521 | DBMET00521 | |
| 0.144 | 0.069 | 0.22 | Mannose-6-phosphate isomerase inhibitor | 0.22 0.021 DBMET00513 0.114 0.113 DBMET00521 | DBMET00513 | |
| 0.127 | 0.053 | 0.128 | Microtubule formation inhibitor | 0.128 0.052 DBMET00513 0.102 0.087 DBMET00521 | DBMET00513 | |
| 0.09 | 0.017 | 0.112 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.112 0.012 DBMET00513 0.073 0.024 DBMET00521 | DBMET00513 | |
| 0.106 | 0.035 | 0.106 | Interleukin 5 antagonist | |||
| 0.115 | 0.045 | 0.199 | Creatine kinase inhibitor | 0.199 0.011 DBMET00513 0.153 0.023 DBMET00521 | DBMET00513 | |
| 0.071 | 0.004 | 0.071 | Carnitine palmitoyltransferase inhibitor | 0.06 0.005 DBMET00521 | ||
| 0.089 | 0.022 | 0.207 | Argininosuccinate synthase inhibitor | 0.133 0.013 DBMET00513 0.207 0.007 DBMET00521 | DBMET00521 | |
| 0.102 | 0.036 | 0.11 | Acetylcholine nicotinic agonist | 0.077 0.061 DBMET00513 0.11 0.031 DBMET00521 | DBMET00521 | |
| 0.085 | 0.019 | 0.098 | Exportin-1 inhibitor | 0.098 0.01 DBMET00513 0.07 0.042 DBMET00521 | DBMET00513 | |
| 0.131 | 0.067 | 0.199 | Toll-Like receptor 2 antagonist | 0.114 0.084 DBMET00513 0.199 0.024 DBMET00521 | DBMET00521 | |
| 0.116 | 0.055 | 0.144 | Acetylcholine release stimulant | 0.144 0.02 DBMET00513 0.142 0.022 DBMET00521 | DBMET00513 | |
| 0.089 | 0.027 | 0.113 | Vanilloid 4 agonist | 0.11 0.011 DBMET00513 0.113 0.009 DBMET00521 | DBMET00521 | |
| 0.134 | 0.073 | 0.257 | Bone formation stimulant | 0.257 0.024 DBMET00521 | DBMET00521 | |
| 0.065 | 0.004 | 0.065 | Carnitine palmitoyltransferase 1 inhibitor | 0.055 0.006 DBMET00521 | ||
| 0.071 | 0.011 | 0.084 | Mannosidase inhibitor | 0.069 0.012 DBMET00513 0.084 0.008 DBMET00521 | DBMET00521 | |
| 0.131 | 0.074 | 0.131 | Amylase inhibitor | 0.129 0.076 DBMET00513 0.118 0.082 DBMET00521 | ||
| 0.101 | 0.045 | 0.103 | Acetylcholine agonist | 0.09 0.055 DBMET00513 0.103 0.045 DBMET00521 | DBMET00521 | |
| 0.09 | 0.035 | 0.202 | GABA aminotransferase inhibitor | 0.104 0.024 DBMET00513 0.202 0.004 DBMET00521 | DBMET00521 | |
| 0.075 | 0.02 | 0.078 | Peroxisome proliferator-activated receptor alpha agonist | 0.078 0.018 DBMET00521 | DBMET00521 | |
| 0.092 | 0.039 | 0.105 | Na+ K+ transporting ATPase inhibitor | 0.105 0.027 DBMET00513 0.102 0.03 DBMET00521 | DBMET00513 | |
| 0.085 | 0.033 | 0.141 | Glycine receptor agonist | 0.093 0.026 DBMET00513 0.141 0.008 DBMET00521 | DBMET00521 | |
| 0.121 | 0.07 | 0.135 | Sphingosine 1-phosphate receptor 4 antagonist | 0.135 0.049 DBMET00513 | DBMET00513 | |
| 0.152 | 0.102 | 0.289 | Lipocortins synthesis antagonist | 0.289 0.023 DBMET00521 | DBMET00521 | |
| 0.141 | 0.091 | 0.171 | Interferon gamma antagonist | 0.16 0.067 DBMET00513 0.171 0.056 DBMET00521 | DBMET00521 | |
| 0.067 | 0.023 | 0.076 | Thromboxane A2 antagonist | 0.076 0.017 DBMET00521 | DBMET00521 | |
| 0.069 | 0.027 | 0.08 | Thromboxane antagonist | 0.08 0.02 DBMET00521 | DBMET00521 | |
| 0.046 | 0.003 | 0.055 | Vanilloid 2 agonist | 0.038 0.005 DBMET00513 0.055 0.003 DBMET00521 | DBMET00521 | |
| 0.074 | 0.032 | 0.115 | Glutamate (mGluR6) antagonist | 0.089 0.016 DBMET00513 0.115 0.006 DBMET00521 | DBMET00521 | |
| 0.072 | 0.031 | 0.078 | Nitric oxide donor | 0.078 0.024 DBMET00521 | DBMET00521 | |
| 0.177 | 0.138 | 0.271 | RNA-directed DNA polymerase inhibitor | 0.271 0.039 DBMET00513 0.197 0.104 DBMET00521 | DBMET00513 | |
| 0.092 | 0.053 | 0.133 | Ornithine decarboxylase inhibitor | 0.087 0.059 DBMET00513 0.133 0.018 DBMET00521 | DBMET00521 | |
| 0.057 | 0.019 | 0.057 | Sphingosine 1-phosphate receptor agonist | 0.056 0.02 DBMET00521 | ||
| 0.07 | 0.032 | 0.096 | Acetylcholine M3 receptor antagonist | 0.096 0.019 DBMET00521 | DBMET00521 | |
| 0.052 | 0.014 | 0.07 | GABA uptake inhibitor | 0.051 0.015 DBMET00513 0.07 0.007 DBMET00521 | DBMET00521 | |
| 0.05 | 0.013 | 0.064 | Kainate receptor agonist | 0.064 0.005 DBMET00513 0.064 0.005 DBMET00521 | DBMET00521 | |
| 0.113 | 0.079 | 0.226 | Aldehyde dehydrogenase inhibitor | 0.159 0.042 DBMET00513 0.226 0.022 DBMET00521 | DBMET00521 | |
| 0.071 | 0.037 | 0.071 | Beta adrenoreceptor antagonist | |||
| 0.05 | 0.018 | 0.097 | Retinoid X receptor agonist | 0.097 0.005 DBMET00521 | DBMET00521 | |
| 0.058 | 0.025 | 0.074 | Lysophosphatidic acid 3 receptor antagonist | 0.061 0.022 DBMET00513 0.074 0.012 DBMET00521 | DBMET00521 | |
| 0.079 | 0.047 | 0.095 | Acetylcholine M4 receptor antagonist | 0.085 0.042 DBMET00513 0.095 0.033 DBMET00521 | DBMET00521 | |
| 0.158 | 0.127 | 0.212 | Neurotrophic factor enhancer | 0.212 0.065 DBMET00513 0.173 0.106 DBMET00521 | DBMET00513 | |
| 0.068 | 0.038 | 0.107 | Acetylcholine M2 receptor antagonist | 0.107 0.019 DBMET00521 | DBMET00521 | |
| 0.103 | 0.073 | 0.18 | Cystathionine beta-synthase inhibitor | 0.18 0.03 DBMET00513 0.149 0.041 DBMET00521 | DBMET00513 | |
| 0.037 | 0.007 | 0.037 | Lysophosphatidic acid receptor 1 agonist | 0.029 0.012 DBMET00513 0.037 0.007 DBMET00521 | ||
| 0.047 | 0.017 | 0.087 | Arginase inhibitor | 0.043 0.02 DBMET00513 0.087 0.005 DBMET00521 | DBMET00521 | |
| 0.106 | 0.077 | 0.223 | Photosensitizer | 0.153 0.029 DBMET00513 0.223 0.009 DBMET00521 | DBMET00521 | |
| 0.062 | 0.033 | 0.062 | Cathepsin D inhibitor | |||
| 0.054 | 0.026 | 0.063 | Adenosine deaminase inhibitor | 0.063 0.018 DBMET00513 0.051 0.029 DBMET00521 | DBMET00513 | |
| 0.051 | 0.023 | 0.114 | Toll-Like receptor 2 agonist | 0.045 0.026 DBMET00513 0.114 0.014 DBMET00521 | DBMET00521 | |
| 0.044 | 0.017 | 0.044 | Antibiotic Aminoglycoside-like | |||
| 0.037 | 0.011 | 0.063 | Urotensin II agonist | 0.063 0.004 DBMET00521 | DBMET00521 | |
| 0.062 | 0.037 | 0.062 | Cathepsin E inhibitor | |||
| 0.051 | 0.027 | 0.051 | Microtubule stabilization | |||
| 0.042 | 0.019 | 0.076 | Glutamate (mGluR8) agonist | 0.064 0.006 DBMET00513 0.076 0.004 DBMET00521 | DBMET00521 | |
| 0.052 | 0.03 | 0.052 | Glycine transporter inhibitor | |||
| 0.136 | 0.113 | 0.296 | Antipruritic | 0.14 0.106 DBMET00513 0.296 0.015 DBMET00521 | DBMET00521 | |
| 0.068 | 0.046 | 0.281 | Potassium channel large-conductance Ca-activated activator | 0.281 0.005 DBMET00521 | DBMET00521 | |
| 0.057 | 0.035 | 0.057 | Adenine nucleotide translocase inhibitor | |||
| 0.033 | 0.014 | 0.079 | Lysine carboxypeptidase inhibitor | 0.025 0.021 DBMET00513 0.079 0.005 DBMET00521 | DBMET00521 | |
| 0.055 | 0.037 | 0.091 | Epithelial sodium channel blocker | 0.056 0.035 DBMET00513 0.091 0.009 DBMET00521 | DBMET00521 | |
| 0.115 | 0.098 | 0.183 | Protein kinase stimulant | 0.14 0.075 DBMET00513 0.183 0.048 DBMET00521 | DBMET00521 | |
| 0.022 | 0.005 | 0.022 | Lysophosphatidic acid receptor 3 agonist | 0.017 0.007 DBMET00513 0.017 0.006 DBMET00521 | ||
| 0.022 | 0.006 | 0.024 | Methylmalonyl-CoA mutase inhibitor | 0.02 0.009 DBMET00513 0.024 0.004 DBMET00521 | DBMET00521 | |
| 0.097 | 0.081 | 0.162 | DOPA decarboxylase inhibitor | 0.162 0.016 DBMET00513 0.129 0.036 DBMET00521 | DBMET00513 | |
| 0.043 | 0.029 | 0.054 | Sphingosine 1-phosphate receptor 1 agonist | 0.054 0.016 DBMET00521 | DBMET00521 | |
| 0.054 | 0.04 | 0.068 | Immunoglobulin Fc receptor antagonist | 0.068 0.013 DBMET00513 | DBMET00513 | |
| 0.021 | 0.008 | 0.049 | Carbonic anhydrase VIII inhibitor | 0.028 0.005 DBMET00513 0.049 0.003 DBMET00521 | DBMET00521 | |
| 0.021 | 0.008 | 0.049 | Carbonic anhydrase X inhibitor | 0.028 0.005 DBMET00513 0.049 0.003 DBMET00521 | DBMET00521 | |
| 0.035 | 0.023 | 0.134 | 1-Alkyl-2-acetylglycerophosphocholine esterase inhibitor | 0.134 0.004 DBMET00521 | DBMET00521 | |
| 0.024 | 0.013 | 0.035 | Prostaglandin F2 alpha agonist | 0.035 0.007 DBMET00521 | DBMET00521 | |
| 0.075 | 0.065 | 0.129 | Glycine receptor antagonist | 0.121 0.018 DBMET00513 0.129 0.014 DBMET00521 | DBMET00521 | |
| 0.064 | 0.054 | 0.109 | Glutamate (mGluR7) antagonist | 0.109 0.007 DBMET00513 0.08 0.027 DBMET00521 | DBMET00513 | |
| 0.028 | 0.018 | 0.036 | Hedgehog signaling activator | 0.036 0.006 DBMET00513 0.029 0.015 DBMET00521 | DBMET00513 | |
| 0.022 | 0.012 | 0.022 | Neuraminidase (Influenza B) inhibitor | 0.021 0.015 DBMET00513 | ||
| 0.061 | 0.052 | 0.078 | Interferon inducer | 0.07 0.035 DBMET00513 0.078 0.026 DBMET00521 | DBMET00521 | |
| 0.031 | 0.022 | 0.031 | Cholesterol ester transfer protein antagonist | |||
| 0.209 | 0.2 | 0.376 | Calcium channel activator | 0.376 0.034 DBMET00513 0.259 0.137 DBMET00521 | DBMET00513 | |
| 0.026 | 0.018 | 0.026 | Toll-Like receptor 4 agonist | |||
| 0.017 | 0.009 | 0.029 | Thromboxane A2 agonist | 0.017 0.008 DBMET00513 0.029 0.004 DBMET00521 | DBMET00521 | |
| 0.052 | 0.044 | 0.076 | Thromboxane synthase inhibitor | 0.076 0.014 DBMET00521 | DBMET00521 | |
| 0.047 | 0.039 | 0.09 | Nicotinic receptor alpha4 subunit antagonist | 0.09 0.01 DBMET00521 | DBMET00521 | |
| 0.033 | 0.026 | 0.047 | Phosphoglycerate kinase inhibitor | 0.038 0.021 DBMET00513 0.047 0.015 DBMET00521 | DBMET00521 | |
| 0.013 | 0.007 | 0.017 | Immunosuppressant Cyclosporine-like | 0.017 0.004 DBMET00521 | DBMET00521 | |
| 0.047 | 0.041 | 0.067 | Squalene epoxidase inhibitor | 0.067 0.016 DBMET00513 0.047 0.041 DBMET00521 | DBMET00513 | |
| 0.016 | 0.011 | 0.026 | Prostacyclin agonist | 0.026 0.007 DBMET00521 | DBMET00521 | |
| 0.039 | 0.034 | 0.072 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.072 0.004 DBMET00513 0.052 0.013 DBMET00521 | DBMET00513 | |
| 0.057 | 0.052 | 0.07 | Selectin antagonist | 0.07 0.042 DBMET00521 | DBMET00521 | |
| 0.009 | 0.005 | 0.009 | Mannitol 2-dehydrogenase inhibitor | |||
| 0.039 | 0.035 | 0.079 | Guanylate cyclase inhibitor | 0.079 0.003 DBMET00513 0.052 0.019 DBMET00521 | DBMET00513 | |
| 0.08 | 0.075 | 0.252 | Potassium channel (Ca-activated) activator | 0.079 0.077 DBMET00513 0.252 0.008 DBMET00521 | DBMET00521 | |
| 0.06 | 0.055 | 0.094 | Acetylcholine M5 receptor agonist | 0.094 0.024 DBMET00513 0.066 0.049 DBMET00521 | DBMET00513 | |
| 0.016 | 0.012 | 0.016 | Vitamin D receptor agonist | 0.016 0.013 DBMET00521 | ||
| 0.049 | 0.046 | 0.057 | Leukotriene B4 antagonist | 0.057 0.032 DBMET00521 | DBMET00521 | |
| 0.025 | 0.022 | 0.044 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.044 0.011 DBMET00513 0.035 0.014 DBMET00521 | DBMET00513 | |
| 0.021 | 0.019 | 0.023 | Isoleucine-tRNA ligase inhibitor | 0.023 0.014 DBMET00513 | DBMET00513 | |
| 0.055 | 0.052 | 0.099 | Purinergic P2X1 antagonist | 0.099 0.017 DBMET00513 0.072 0.03 DBMET00521 | DBMET00513 | |
| 0.015 | 0.014 | 0.015 | KiSS-1 receptor antagonist | |||
| 0.055 | 0.054 | 0.067 | Ryanodine receptor antagonist | 0.067 0.021 DBMET00513 0.06 0.038 DBMET00521 | DBMET00513 | |
| 0.031 | 0.03 | 0.031 | Renin inhibitor | |||
| 0.039 | 0.038 | 0.039 | Phosphorylase inhibitor | |||
| 0.136 | 0.137 | 0.185 | Non-steroidal antiinflammatory agent | 0.185 0.083 DBMET00521 | DBMET00521 | |
| 0.058 | 0.059 | 0.06 | Beta 2 adrenoreceptor agonist | 0.06 0.05 DBMET00521 | DBMET00521 | |
| 0.059 | 0.061 | 0.073 | Calcium channel P-type blocker | 0.073 0.023 DBMET00513 | DBMET00513 | |
| 0.073 | 0.075 | 0.136 | Histamine N-methyltransferase inhibitor | 0.136 0.02 DBMET00513 0.124 0.027 DBMET00521 | DBMET00513 | |
| 0.015 | 0.017 | 0.021 | Telomerase stimulant | 0.021 0.007 DBMET00513 | DBMET00513 | |
| 0.124 | 0.126 | 0.143 | Melanin inhibitor | 0.142 0.092 DBMET00513 0.143 0.092 DBMET00521 | DBMET00521 | |
| 0.025 | 0.028 | 0.041 | Purinergic P2Y15 antagonist | 0.041 0.006 DBMET00513 0.03 0.017 DBMET00521 | DBMET00513 | |
| 0.051 | 0.054 | 0.092 | Carbonic anhydrase stimulant | 0.062 0.038 DBMET00513 0.092 0.021 DBMET00521 | DBMET00521 | |
| 0.008 | 0.012 | 0.015 | Thromboxane agonist | 0.015 0.005 DBMET00521 | DBMET00521 | |
| 0.027 | 0.031 | 0.041 | Calcitonin receptor agonist | 0.041 0.02 DBMET00521 | DBMET00521 | |
| 0.031 | 0.035 | 0.05 | Nicotinic receptor beta4 subunit antagonist | 0.05 0.016 DBMET00521 | DBMET00521 | |
| 0.083 | 0.087 | 0.43 | Topoisomerase I inhibitor | 0.43 0.005 DBMET00513 0.101 0.069 DBMET00521 | DBMET00513 | |
| 0.027 | 0.031 | 0.033 | ATP citrate lysase inhibitor | 0.033 0.02 DBMET00521 | DBMET00521 | |
| 0.041 | 0.046 | 0.074 | Cholesterol esterase inhibitor | 0.074 0.009 DBMET00521 | DBMET00521 | |
| 0.025 | 0.03 | 0.04 | Estrogen-related receptor gamma antagonist | 0.04 0.005 DBMET00513 0.03 0.016 DBMET00521 | DBMET00513 | |
| 0.013 | 0.018 | 0.021 | Aminopeptidase A inhibitor | 0.021 0.01 DBMET00521 | DBMET00521 | |
| 0.029 | 0.034 | 0.047 | Glutamate (mGluR3) agonist | 0.036 0.014 DBMET00513 0.047 0.006 DBMET00521 | DBMET00521 | |
| 0.067 | 0.072 | 0.075 | Keratolytic | 0.075 0.055 DBMET00513 0.074 0.057 DBMET00521 | DBMET00513 | |
| 0.013 | 0.019 | 0.04 | Ileal bile acid transport inhibitor | 0.04 0.004 DBMET00521 | DBMET00521 | |
| 0.008 | 0.016 | 0.02 | Glutamate (mGluR6) agonist | 0.015 0.005 DBMET00513 0.02 0.004 DBMET00521 | DBMET00521 | |
| 0.061 | 0.068 | 0.074 | Calcium channel L-type blocker | 0.074 0.046 DBMET00521 | DBMET00521 | |
| 0.03 | 0.038 | 0.049 | Ceramide glucosyltransferase inhibitor | 0.034 0.028 DBMET00513 0.049 0.008 DBMET00521 | DBMET00521 | |
| 0.037 | 0.045 | 0.069 | AICAR transformylase inhibitor | 0.052 0.02 DBMET00513 0.069 0.01 DBMET00521 | DBMET00521 | |
| 0.042 | 0.052 | 0.059 | Dopamine beta hydroxylase inhibitor | 0.059 0.016 DBMET00513 | DBMET00513 | |
| 0.05 | 0.06 | 0.059 | Acetylcholine M5 receptor antagonist | 0.059 0.043 DBMET00513 0.059 0.044 DBMET00521 | DBMET00521 | |
| 0.022 | 0.033 | 0.033 | Squalene synthetase inhibitor | 0.033 0.021 DBMET00521 | DBMET00521 | |
| 0.102 | 0.114 | 0.169 | Lipid peroxidase inhibitor | 0.169 0.056 DBMET00521 | DBMET00521 | |
| 0.041 | 0.053 | 0.047 | Bombesin 2 receptor antagonist | 0.047 0.037 DBMET00521 | DBMET00521 | |
| 0.03 | 0.044 | 0.039 | Adenosine uptake inhibitor | 0.039 0.013 DBMET00513 0.036 0.02 DBMET00521 | DBMET00513 | |
| 0.036 | 0.049 | 0.08 | Thymidylate synthase inhibitor | 0.049 0.028 DBMET00513 0.08 0.007 DBMET00521 | DBMET00521 | |
| 0.009 | 0.023 | 0.019 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | 0.019 0.004 DBMET00513 0.013 0.009 DBMET00521 | DBMET00513 | |
| 0.015 | 0.029 | 0.02 | Antibiotic Anthracycline-like | 0.02 0.01 DBMET00513 | DBMET00513 | |
| 0.135 | 0.149 | 0.295 | Anticonvulsant | 0.295 0.042 DBMET00521 | DBMET00521 | |
| 0.027 | 0.041 | 0.039 | Carboxypeptidase B inhibitor | 0.039 0.014 DBMET00521 | DBMET00521 | |
| 0.023 | 0.039 | 0.027 | 1,3-Beta-glucan synthase inhibitor | 0.027 0.022 DBMET00521 | DBMET00521 | |
| 0.009 | 0.025 | 0.013 | Integrin alphaVbeta6 antagonist | 0.013 0.011 DBMET00521 | DBMET00521 | |
| 0.011 | 0.027 | 0.018 | Purinergic P2Y1 agonist | 0.018 0.008 DBMET00513 | DBMET00513 | |
| 0.123 | 0.14 | 0.298 | DNA methyltransferase I inhibitor | 0.139 0.117 DBMET00513 0.298 0.027 DBMET00521 | DBMET00521 | |
| 0.063 | 0.081 | 0.131 | Calcium antagonist | 0.131 0.029 DBMET00513 | DBMET00513 | |
| 0.016 | 0.035 | 0.026 | Retinoid X beta receptor antagonist | 0.02 0.015 DBMET00513 0.026 0.006 DBMET00521 | DBMET00521 | |
| 0.015 | 0.035 | 0.025 | Lysophosphatidic acid 1 receptor antagonist | 0.025 0.01 DBMET00521 | DBMET00521 | |
| 0.021 | 0.041 | 0.048 | Prostaglandin D2 agonist | 0.048 0.009 DBMET00521 | DBMET00521 | |
| 0.049 | 0.069 | 0.164 | NMDA receptor agonist | 0.091 0.023 DBMET00513 0.164 0.006 DBMET00521 | DBMET00521 | |
| 0.029 | 0.05 | 0.061 | Dopamine D5 agonist | 0.061 0.011 DBMET00513 0.037 0.031 DBMET00521 | DBMET00513 | |
| 0.004 | 0.024 | 0.009 | Integrin alpha5beta6 antagonist | 0.009 0.004 DBMET00521 | DBMET00521 | |
| 0.035 | 0.056 | 0.071 | Adenylate cyclase 1 inhibitor | 0.071 0.012 DBMET00513 | DBMET00513 | |
| 0.092 | 0.116 | 0.144 | Cyclooxygenase 3 inhibitor | 0.144 0.053 DBMET00513 0.136 0.06 DBMET00521 | DBMET00513 | |
| 0.012 | 0.036 | 0.029 | Prostaglandin EP2 agonist | 0.029 0.013 DBMET00521 | DBMET00521 | |
| 0.013 | 0.038 | 0.018 | Estrogen-related receptor gamma agonist | 0.017 0.016 DBMET00513 0.018 0.015 DBMET00521 | DBMET00521 | |
| 0.028 | 0.054 | 0.044 | Macrophage elastase inhibitor | 0.044 0.029 DBMET00521 | DBMET00521 | |
| 0.007 | 0.033 | 0.016 | Carbonic anhydrase XI inhibitor | 0.015 0.007 DBMET00513 0.016 0.005 DBMET00521 | DBMET00521 | |
| 0.08 | 0.106 | 0.127 | Carbonic anhydrase XV inhibitor | 0.127 0.042 DBMET00513 0.111 0.054 DBMET00521 | DBMET00513 | |
| 0.218 | 0.245 | 0.309 | Calcium channel L-type activator | 0.309 0.15 DBMET00513 | DBMET00513 | |
| 0.013 | 0.04 | 0.018 | CXC chemokine 5 receptor antagonist | 0.018 0.012 DBMET00513 | DBMET00513 | |
| 0.11 | 0.138 | 0.396 | Growth hormone agonist | 0.396 0.016 DBMET00521 | DBMET00521 | |
| 0.046 | 0.075 | 0.155 | Sphingosine 1-phosphate receptor 4 agonist | 0.101 0.024 DBMET00513 0.155 0.008 DBMET00521 | DBMET00521 | |
| 0.047 | 0.076 | 0.061 | Leukotriene antagonist | 0.061 0.05 DBMET00521 | DBMET00521 | |
| 0.026 | 0.055 | 0.048 | Glutamate (mGluR3) antagonist | 0.036 0.026 DBMET00513 0.048 0.014 DBMET00521 | DBMET00521 | |
| 0.072 | 0.103 | 0.113 | Granulocyte macrophage colony stimulating factor agonist | 0.113 0.021 DBMET00513 0.083 0.066 DBMET00521 | DBMET00513 | |
| 0.043 | 0.074 | 0.057 | Angiotensin-converting enzyme inhibitor | 0.057 0.034 DBMET00521 | DBMET00521 | |
| 0.156 | 0.189 | 0.28 | 5 Hydroxytryptamine 3E antagonist | 0.28 0.007 DBMET00513 0.173 0.125 DBMET00521 | DBMET00513 | |
| 0.082 | 0.115 | 0.232 | Folate antagonist | 0.232 0.006 DBMET00521 | DBMET00521 | |
| 0.03 | 0.063 | 0.108 | Neurotensin receptor antagonist | 0.108 0.013 DBMET00521 | DBMET00521 | |
| 0.018 | 0.051 | 0.03 | Prostaglandin agonist | 0.03 0.023 DBMET00521 | DBMET00521 | |
| 0.039 | 0.072 | 0.051 | Cytokine production stimulant | 0.051 0.026 DBMET00513 | DBMET00513 | |
| 0.04 | 0.076 | 0.052 | Sphingosine kinase 2 inhibitor | 0.052 0.043 DBMET00513 | DBMET00513 | |
| 0.021 | 0.056 | 0.051 | Retinoid X alpha receptor agonist | 0.031 0.029 DBMET00513 0.051 0.014 DBMET00521 | DBMET00521 | |
| 0.018 | 0.054 | 0.03 | Integrin alpha2beta1 antagonist | 0.03 0.013 DBMET00513 0.029 0.014 DBMET00521 | DBMET00513 | |
| 0.021 | 0.058 | 0.027 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.027 0.018 DBMET00513 | DBMET00513 | |
| 0.014 | 0.051 | 0.034 | Uridine phosphorylase inhibitor | 0.034 0.015 DBMET00513 | DBMET00513 | |
| 0.039 | 0.077 | 0.08 | Nicotinic receptor alpha7 subunit antagonist | 0.08 0.017 DBMET00521 | DBMET00521 | |
| 0.017 | 0.055 | 0.027 | Glutamate (mGluR1) agonist | 0.027 0.013 DBMET00513 0.026 0.014 DBMET00521 | DBMET00513 | |
| 0.036 | 0.074 | 0.047 | Heme oxygenase inhibitor | 0.047 0.019 DBMET00513 | DBMET00513 | |
| 0.067 | 0.107 | 0.133 | Alcohol dehydrogenase inhibitor | 0.101 0.051 DBMET00513 0.133 0.027 DBMET00521 | DBMET00521 | |
| 0.038 | 0.077 | 0.124 | Neuraminidase inhibitor | 0.124 0.009 DBMET00513 | DBMET00513 | |
| 0.047 | 0.087 | 0.061 | Leukotriene C antagonist | 0.061 0.026 DBMET00521 | DBMET00521 | |
| 0.065 | 0.106 | 0.091 | MAP kinase kinase 7 inhibitor | 0.091 0.023 DBMET00513 0.078 0.053 DBMET00521 | DBMET00513 | |
| 0.025 | 0.066 | 0.051 | Integrin alpha2 antagonist | 0.042 0.019 DBMET00513 0.051 0.011 DBMET00521 | DBMET00521 | |
| 0.051 | 0.092 | 0.201 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.201 0.009 DBMET00513 0.069 0.062 DBMET00521 | DBMET00513 | |
| 0.014 | 0.056 | 0.021 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.021 0.014 DBMET00513 | DBMET00513 | |
| 0.014 | 0.056 | 0.028 | Acetylcholine M4 receptor agonist | 0.028 0.024 DBMET00513 | DBMET00513 | |
| 0.009 | 0.052 | 0.04 | Prostaglandin H2 antagonist | 0.04 0.005 DBMET00521 | DBMET00521 | |
| 0.045 | 0.088 | 0.074 | 5 Hydroxytryptamine 3 agonist | 0.074 0.031 DBMET00513 0.064 0.042 DBMET00521 | DBMET00513 | |
| 0.071 | 0.114 | 0.16 | Carbonic anhydrase III inhibitor | 0.145 0.03 DBMET00513 0.16 0.025 DBMET00521 | DBMET00521 | |
| 0.034 | 0.077 | 0.105 | Prostaglandin EP2 antagonist | 0.105 0.018 DBMET00521 | DBMET00521 | |
| 0.028 | 0.072 | 0.04 | Thymidine kinase inhibitor | 0.04 0.03 DBMET00513 | DBMET00513 | |
| 0.064 | 0.109 | 0.126 | HIV-1 integrase (Overall Integration) inhibitor | 0.126 0.036 DBMET00513 0.106 0.049 DBMET00521 | DBMET00513 | |
| 0.047 | 0.092 | 0.096 | Carbonic anhydrase XIII inhibitor | 0.078 0.051 DBMET00513 0.096 0.04 DBMET00521 | DBMET00521 | |
| 0.023 | 0.068 | 0.038 | Retinoid X alpha receptor antagonist | 0.032 0.028 DBMET00513 0.038 0.018 DBMET00521 | DBMET00521 | |
| 0.016 | 0.062 | 0.035 | Calcium-sensing receptor agonist | 0.035 0.009 DBMET00521 | DBMET00521 | |
| 0.083 | 0.129 | 0.132 | Factor V inhibitor | 0.132 0.029 DBMET00521 | DBMET00521 | |
| 0.123 | 0.169 | 0.158 | Heat shock protein 70 antagonist | 0.155 0.036 DBMET00513 0.158 0.031 DBMET00521 | DBMET00521 | |
| 0.056 | 0.103 | 0.111 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.111 0.008 DBMET00513 0.073 0.053 DBMET00521 | DBMET00513 | |
| 0.023 | 0.071 | 0.087 | 2,3-Oxidosqualene-lanosterol cyclase inhibitor | 0.087 0.004 DBMET00513 | DBMET00513 | |
| 0.012 | 0.06 | 0.031 | Leukotriene B4 receptor 1 antagonist | 0.031 0.017 DBMET00521 | DBMET00521 | |
| 0.025 | 0.074 | 0.045 | Retinoid X receptor antagonist | 0.035 0.031 DBMET00513 0.045 0.017 DBMET00521 | DBMET00521 | |
| 0.022 | 0.073 | 0.063 | Dihydropteroate synthase inhibitor | 0.057 0.013 DBMET00513 0.063 0.01 DBMET00521 | DBMET00521 | |
| 0.011 | 0.064 | 0.026 | Kynurenine 3 monooxygenase inhibitor | 0.026 0.019 DBMET00521 | DBMET00521 | |
| 0.003 | 0.056 | 0.008 | Phosphoribosylglycinamide formyltransferase inhibitor | 0.008 0.004 DBMET00521 | DBMET00521 | |
| 0.021 | 0.075 | 0.052 | Oxytocin agonist | 0.052 0.022 DBMET00513 0.046 0.027 DBMET00521 | DBMET00513 | |
| 0.011 | 0.064 | 0.02 | Leukotriene B4 receptor 2 antagonist | 0.02 0.019 DBMET00521 | DBMET00521 | |
| 0.061 | 0.114 | 0.106 | Glutathione S-transferase inhibitor | 0.094 0.043 DBMET00513 0.106 0.032 DBMET00521 | DBMET00521 | |
| 0.025 | 0.08 | 0.046 | Glutamate (mGluR8) antagonist | 0.046 0.011 DBMET00521 | DBMET00521 | |
| 0.039 | 0.094 | 0.651 | Adrenaline uptake inhibitor | 0.651 0.003 DBMET00513 | DBMET00513 | |
| 0.004 | 0.059 | 0.033 | N-Acetylated alpha-linked acidic dipeptidase inhibitor | 0.033 0.005 DBMET00521 | DBMET00521 | |
| 0.112 | 0.168 | 0.281 | DNA methylase inhibitor | 0.281 0.034 DBMET00521 | DBMET00521 | |
| 0.029 | 0.086 | 0.04 | Leukotriene C4 antagonist | 0.04 0.024 DBMET00521 | DBMET00521 | |
| 0.008 | 0.064 | 0.016 | Nicotinic alpha4 receptor agonist | 0.016 0.012 DBMET00513 | DBMET00513 | |
| 0.005 | 0.061 | 0.015 | G-protein-coupled receptor 120 agonist | 0.015 0.014 DBMET00521 | DBMET00521 | |
| 0.022 | 0.079 | 0.055 | Acetylcholine M1 receptor agonist | 0.055 0.023 DBMET00513 0.038 0.034 DBMET00521 | DBMET00513 | |
| 0.011 | 0.069 | 0.033 | Glutamate (mGluR1a) agonist | 0.027 0.01 DBMET00513 0.033 0.008 DBMET00521 | DBMET00521 | |
| 0.067 | 0.126 | 0.122 | Lanosterol 14 alpha demethylase inhibitor | 0.122 0.029 DBMET00513 0.088 0.075 DBMET00521 | DBMET00513 | |
| 0.064 | 0.123 | 0.138 | Falcipain 3 inhibitor | 0.138 0.042 DBMET00513 0.091 0.079 DBMET00521 | DBMET00513 | |
| 0.036 | 0.097 | 0.051 | Heparanase inhibitor | 0.051 0.042 DBMET00521 | DBMET00521 | |
| 0.066 | 0.128 | 0.108 | D-Ala-D-Ala ligase inhibitor | 0.108 0.021 DBMET00513 0.08 0.069 DBMET00521 | DBMET00513 | |
| 0.044 | 0.106 | 0.219 | Neuraminidase (influenza) inhibitor | 0.219 0.004 DBMET00513 | DBMET00513 | |
| 0.044 | 0.107 | 0.072 | Protease 3C (Human rhinovirus) inhibitor | 0.072 0.035 DBMET00513 | DBMET00513 | |
| 0.073 | 0.137 | 0.093 | Phosphodiesterase 6D inhibitor | 0.093 0.068 DBMET00513 | DBMET00513 | |
| 0.174 | 0.238 | 0.568 | Toll-Like receptor agonist | 0.568 0.021 DBMET00521 | DBMET00521 | |
| 0.051 | 0.115 | 0.081 | Androgen antagonist | 0.081 0.064 DBMET00513 | DBMET00513 | |
| 0.032 | 0.097 | 0.095 | NMDA receptor glycine site agonist | 0.095 0.019 DBMET00513 0.082 0.027 DBMET00521 | DBMET00513 | |
| 0.014 | 0.079 | 0.063 | Complement C3a chemotactic receptor antagonist | 0.063 0.02 DBMET00521 | DBMET00521 | |
| 0.023 | 0.091 | 0.034 | Tryptophan 5 hydroxylase inhibitor | 0.034 0.031 DBMET00513 | DBMET00513 | |
| 0.041 | 0.109 | 0.069 | Pregnane X receptor antagonist | 0.069 0.015 DBMET00513 0.062 0.026 DBMET00521 | DBMET00513 | |
| 0.073 | 0.144 | 0.117 | Glutamate (mGluR7) agonist | 0.117 0.034 DBMET00513 0.116 0.034 DBMET00521 | DBMET00513 | |
| 0.037 | 0.108 | 0.112 | Neuronal nicotinic receptor antagonist | 0.07 0.045 DBMET00513 0.112 0.02 DBMET00521 | DBMET00521 | |
| 0.011 | 0.083 | 0.019 | Caspase 8 inhibitor | 0.019 0.014 DBMET00521 | DBMET00521 | |
| 0.032 | 0.104 | 0.052 | Topoisomerase II beta inhibitor | 0.052 0.03 DBMET00513 | DBMET00513 | |
| 0.052 | 0.124 | 0.121 | Carbonic anhydrase VI inhibitor | 0.088 0.048 DBMET00513 0.121 0.029 DBMET00521 | DBMET00521 | |
| 0.023 | 0.097 | 0.056 | AMPA 4 receptor antagonist | 0.04 0.026 DBMET00513 0.056 0.012 DBMET00521 | DBMET00521 | |
| 0.05 | 0.124 | 0.074 | Potassium channel (Tandem pore domain) blocker | 0.074 0.051 DBMET00513 | DBMET00513 | |
| 0.014 | 0.087 | 0.026 | LFA antagonist | 0.026 0.022 DBMET00521 | DBMET00521 | |
| 0.021 | 0.095 | 0.074 | Carbonic anhydrase VB inhibitor | 0.074 0.025 DBMET00513 0.069 0.029 DBMET00521 | DBMET00513 | |
| 0.042 | 0.116 | 0.082 | Cathepsin G inhibitor | 0.082 0.042 DBMET00521 | DBMET00521 | |
| 0.053 | 0.129 | 0.072 | MDM2 inhibitor | 0.072 0.034 DBMET00513 0.072 0.034 DBMET00521 | DBMET00521 | |
| 0.014 | 0.091 | 0.032 | Peptide deformylase inhibitor | 0.027 0.026 DBMET00513 0.032 0.019 DBMET00521 | DBMET00521 | |
| 0.03 | 0.11 | 0.054 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.054 0.037 DBMET00513 | DBMET00513 | |
| 0.098 | 0.177 | 0.251 | Hemostatic | 0.251 0.022 DBMET00521 | DBMET00521 | |
| 0.034 | 0.114 | 0.054 | Botulinum neurotoxin type A inhibitor | 0.054 0.048 DBMET00513 | DBMET00513 | |
| 0.027 | 0.108 | 0.042 | GABA B receptor antagonist | 0.042 0.032 DBMET00521 | DBMET00521 | |
| 0.012 | 0.095 | 0.027 | Nicotinic acid receptor 2 antagonist | 0.027 0.017 DBMET00513 | DBMET00513 | |
| 0.038 | 0.122 | 0.068 | Protein kinase C beta inhibitor | 0.068 0.052 DBMET00513 | DBMET00513 | |
| 0.012 | 0.097 | 0.033 | 5-Alpha-reductase inhibitor | 0.033 0.031 DBMET00521 | DBMET00521 | |
| 0.029 | 0.114 | 0.052 | Glutamate (mGluR group III) antagonist | 0.052 0.019 DBMET00513 0.052 0.019 DBMET00521 | DBMET00521 | |
| 0.124 | 0.209 | 0.211 | Cyclic AMP phosphodiesterase inhibitor | 0.211 0.086 DBMET00513 | DBMET00513 | |
| 0.053 | 0.141 | 0.092 | Mediator release inhibitor | 0.092 0.08 DBMET00521 | DBMET00521 | |
| 0.052 | 0.14 | 0.107 | Antineoplastic alkaloid | 0.107 0.043 DBMET00521 | DBMET00521 | |
| 0.005 | 0.094 | 0.048 | Bradykinin B2 receptor antagonist | 0.048 0.008 DBMET00521 | DBMET00521 | |
| 0.047 | 0.136 | 0.113 | NMDA receptor antagonist | 0.113 0.039 DBMET00521 | DBMET00521 | |
| 0.008 | 0.099 | 0.018 | Integrin beta6 antagonist | 0.018 0.005 DBMET00521 | DBMET00521 | |
| 0.008 | 0.101 | 0.025 | Retinoid X gamma receptor agonist | 0.025 0.014 DBMET00521 | DBMET00521 | |
| 0.025 | 0.119 | 0.058 | Histamine H1 receptor agonist | 0.058 0.01 DBMET00513 | DBMET00513 | |
| 0.026 | 0.12 | 0.078 | Diacylglycerol O-acyltransferase inhibitor | 0.078 0.015 DBMET00521 | DBMET00521 | |
| 0.009 | 0.105 | 0.022 | Integrin alphaVbeta1 antagonist | 0.022 0.01 DBMET00521 | DBMET00521 | |
| 0.033 | 0.129 | 0.053 | CD45 antagonist | 0.053 0.029 DBMET00521 | DBMET00521 | |
| 0.027 | 0.125 | 0.043 | Aldosterone antagonist | 0.043 0.041 DBMET00513 | DBMET00513 | |
| 0.01 | 0.109 | 0.053 | Kainate receptor 2 antagonist | 0.032 0.028 DBMET00513 0.053 0.014 DBMET00521 | DBMET00521 | |
| 0.012 | 0.111 | 0.033 | Free fatty acid receptor 1 antagonist | 0.033 0.024 DBMET00521 | DBMET00521 | |
| 0.102 | 0.202 | 0.194 | CF transmembrane conductance regulator agonist | 0.194 0.025 DBMET00513 | DBMET00513 | |
| 0.013 | 0.113 | 0.025 | Thyroid hormone agonist | 0.025 0.02 DBMET00521 | DBMET00521 | |
| 0.016 | 0.117 | 0.086 | NMDA 2A receptor antagonist | 0.086 0.018 DBMET00521 | DBMET00521 | |
| 0.013 | 0.115 | 0.029 | Acid ceramidase inhibitor | 0.029 0.011 DBMET00513 | DBMET00513 | |
| 0.06 | 0.162 | 0.138 | DNA polymerase I inhibitor | 0.138 0.056 DBMET00521 | DBMET00521 | |
| 0.007 | 0.109 | 0.02 | Retinoid X beta receptor agonist | 0.02 0.016 DBMET00521 | DBMET00521 | |
| 0.02 | 0.122 | 0.068 | Histamine H2 receptor agonist | 0.068 0.011 DBMET00513 | DBMET00513 | |
| 0.026 | 0.129 | 0.058 | Glutamate (mGluR4) antagonist | 0.051 0.019 DBMET00513 0.058 0.015 DBMET00521 | DBMET00521 | |
| 0.022 | 0.126 | 0.058 | Neutrophil collagenase inhibitor | 0.058 0.053 DBMET00521 | DBMET00521 | |
| 0.099 | 0.203 | 0.153 | Sphingosine 1-phosphate receptor 5 antagonist | 0.153 0.057 DBMET00513 0.141 0.078 DBMET00521 | DBMET00513 | |
| 0.004 | 0.111 | 0.018 | Free fatty acid receptor 1 agonist | 0.018 0.012 DBMET00521 | DBMET00521 | |
| 0.03 | 0.14 | 0.076 | Carbonic anhydrase VA inhibitor | 0.075 0.041 DBMET00513 0.076 0.04 DBMET00521 | DBMET00521 | |
| 0.021 | 0.131 | 0.062 | Nerve growth factor antagonist | 0.062 0.008 DBMET00513 0.04 0.037 DBMET00521 | DBMET00513 | |
| 0.012 | 0.126 | 0.027 | Retinoid X gamma receptor antagonist | 0.027 0.018 DBMET00521 | DBMET00521 | |
| 0.06 | 0.175 | 0.105 | Protein kinase C gamma inhibitor | 0.105 0.069 DBMET00513 | DBMET00513 | |
| 0.018 | 0.133 | 0.032 | Melatonin receptor 1A agonist | 0.032 0.026 DBMET00513 | DBMET00513 | |
| 0.005 | 0.121 | 0.019 | Cyclin T1 inhibitor | 0.019 0.012 DBMET00513 | DBMET00513 | |
| 0.01 | 0.128 | 0.035 | Caspase 2 inhibitor | 0.035 0.019 DBMET00521 | DBMET00521 | |
| 0.014 | 0.132 | 0.027 | Thymidine phosphorylase inhibitor | 0.027 0.016 DBMET00513 | DBMET00513 | |
| 0.059 | 0.177 | 0.096 | MAP kinase kinase 1 inhibitor | 0.096 0.062 DBMET00513 | DBMET00513 | |
| 0.032 | 0.15 | 0.105 | Sphingosine 1-phosphate receptor 5 agonist | 0.105 0.008 DBMET00521 | DBMET00521 | |
| 0.04 | 0.159 | 0.055 | Lipocortins synthesis agonist | 0.055 0.048 DBMET00521 | DBMET00521 | |
| 0.015 | 0.137 | 0.043 | Integrin alpha5beta1 antagonist | 0.043 0.025 DBMET00521 | DBMET00521 | |
| 0.004 | 0.127 | 0.015 | NMDA receptor phencyclidine site antagonist | 0.015 0.01 DBMET00513 | DBMET00513 | |
| 0.032 | 0.156 | 0.068 | Dihydroorotate oxidase inhibitor | 0.068 0.019 DBMET00513 | DBMET00513 | |
| 0.025 | 0.15 | 0.07 | Carbonic anhydrase V inhibitor | 0.07 0.043 DBMET00513 0.068 0.045 DBMET00521 | DBMET00513 | |
| 0.004 | 0.129 | 0.021 | Integrin alpha4 antagonist | 0.021 0.02 DBMET00521 | DBMET00521 | |
| 0.007 | 0.132 | 0.093 | GP IIb/IIIa receptor antagonist | 0.093 0.019 DBMET00521 | DBMET00521 | |
| 0.012 | 0.14 | 0.03 | MAP3K8 inhibitor | 0.03 0.018 DBMET00513 | DBMET00513 | |
| 0.034 | 0.163 | 0.141 | CYP2A6 inhibitor | 0.141 0.019 DBMET00513 | DBMET00513 | |
| 0.055 | 0.183 | 0.1 | mTOR complex 2 inhibitor | 0.1 0.033 DBMET00513 | DBMET00513 | |
| 0.008 | 0.138 | 0.037 | AMPA 3 receptor antagonist | 0.037 0.015 DBMET00521 | DBMET00521 | |
| 0.018 | 0.148 | 0.038 | Glutamate (mGluR1a) antagonist | 0.038 0.032 DBMET00513 | DBMET00513 | |
| 0.008 | 0.138 | 0.036 | Prostacyclin antagonist | 0.036 0.021 DBMET00521 | DBMET00521 | |
| 0.038 | 0.17 | 0.084 | Caspase 9 inhibitor | 0.084 0.021 DBMET00521 | DBMET00521 | |
| 0.019 | 0.152 | 0.204 | Dopamine transporter inhibitor | 0.204 0.004 DBMET00513 | DBMET00513 | |
| 0.009 | 0.143 | 0.026 | Liver X receptor beta antagonist | 0.026 0.023 DBMET00521 | DBMET00521 | |
| 0.01 | 0.144 | 0.05 | Diamine oxidase inhibitor | 0.05 0.014 DBMET00513 | DBMET00513 | |
| 0.053 | 0.188 | 0.092 | Bromodomain-containing protein 2 inhibitor | 0.092 0.052 DBMET00513 | DBMET00513 | |
| 0.058 | 0.195 | 0.126 | Caspase 3 inhibitor | 0.126 0.052 DBMET00521 | DBMET00521 | |
| 0.01 | 0.148 | 0.104 | Integrin antagonist | 0.104 0.016 DBMET00521 | DBMET00521 | |
| 0.019 | 0.156 | 0.034 | Protein kinase (CK2) beta inhibitor | 0.034 0.021 DBMET00513 | DBMET00513 | |
| 0.025 | 0.163 | 0.065 | Androgen agonist | 0.065 0.035 DBMET00513 | DBMET00513 | |
| 0.045 | 0.183 | 0.084 | Histamine H2 receptor antagonist | 0.084 0.057 DBMET00513 | DBMET00513 | |
| 0.012 | 0.151 | 0.035 | NMDA receptor subunit 3A antagonist | 0.035 0.029 DBMET00521 | DBMET00521 | |
| 0.009 | 0.149 | 0.04 | Kainate receptor antagonist | 0.04 0.029 DBMET00521 | DBMET00521 | |
| 0.005 | 0.148 | 0.019 | Adenosine kinase inhibitor | 0.019 0.017 DBMET00513 | DBMET00513 | |
| 0.013 | 0.157 | 0.067 | Alpha 1d adrenoreceptor agonist | 0.067 0.008 DBMET00513 | DBMET00513 | |
| 0.007 | 0.155 | 0.022 | Integrin beta5 antagonist | 0.022 0.013 DBMET00521 | DBMET00521 | |
| 0.017 | 0.168 | 0.044 | NMDA receptor subunit 3B antagonist | 0.044 0.03 DBMET00521 | DBMET00521 | |
| 0.027 | 0.181 | 0.071 | Autotaxin inhibitor | 0.071 0.022 DBMET00521 | DBMET00521 | |
| 0.008 | 0.163 | 0.029 | Protease (Human cytomegalovirus) inhibitor | 0.029 0.008 DBMET00513 | DBMET00513 | |
| 0.032 | 0.189 | 0.054 | DNA helicase inhibitor | 0.054 0.038 DBMET00521 | DBMET00521 | |
| 0.057 | 0.214 | 0.105 | Hematopoietic | 0.105 0.031 DBMET00521 | DBMET00521 | |
| 0.051 | 0.217 | 0.085 | Transcription factor NF kappa B stimulant | 0.085 0.059 DBMET00521 | DBMET00521 | |
| 0.013 | 0.179 | 0.031 | Peroxisome proliferator-activated receptor delta antagonist | 0.031 0.027 DBMET00521 | DBMET00521 | |
| 0.006 | 0.173 | 0.038 | Nicotinic alpha4beta2 receptor agonist | 0.038 0.009 DBMET00513 | DBMET00513 | |
| 0.045 | 0.212 | 0.12 | Chelator | 0.12 0.053 DBMET00521 | DBMET00521 | |
| 0.136 | 0.305 | 0.553 | Toll-Like receptor 7 agonist | 0.553 0.023 DBMET00521 | DBMET00521 | |
| 0.123 | 0.294 | 0.195 | Neuropeptide Y2 antagonist | 0.195 0.128 DBMET00513 0.185 0.149 DBMET00521 | DBMET00513 | |
| 0.02 | 0.191 | 0.066 | Glucagon-like peptide 1 agonist | 0.066 0.044 DBMET00521 | DBMET00521 | |
| 0.013 | 0.186 | 0.046 | Fructose-1,6-bisphosphatase inhibitor | 0.046 0.029 DBMET00513 0.045 0.03 DBMET00521 | DBMET00513 | |
| 0.009 | 0.183 | 0.021 | Factor XIII inhibitor | 0.021 0.015 DBMET00513 | DBMET00513 | |
| 0.016 | 0.191 | 0.044 | Cholecystokinin B agonist | 0.044 0.02 DBMET00521 | DBMET00521 | |
| 0.005 | 0.183 | 0.047 | Leukotriene A4 hydrolase inhibitor | 0.047 0.021 DBMET00521 | DBMET00521 | |
| 0.04 | 0.218 | 0.165 | Bronchodilator | 0.165 0.026 DBMET00521 | DBMET00521 | |
| 0.01 | 0.189 | 0.028 | Epoxide hydrolase 1 inhibitor | 0.028 0.027 DBMET00513 | DBMET00513 | |
| 0.018 | 0.198 | 0.071 | Elastase inhibitor | 0.071 0.021 DBMET00521 | DBMET00521 | |
| 0.026 | 0.211 | 0.089 | Nicotinic alpha3beta2 receptor antagonist | 0.089 0.01 DBMET00513 | DBMET00513 | |
| 0.021 | 0.206 | 0.04 | VCAM-1 antagonist | 0.04 0.027 DBMET00521 | DBMET00521 | |
| 0.007 | 0.192 | 0.03 | Integrin alphaVbeta3 antagonist | 0.03 0.008 DBMET00521 | DBMET00521 | |
| 0.022 | 0.208 | 0.121 | Lipase inhibitor | 0.121 0.018 DBMET00521 | DBMET00521 | |
| 0.021 | 0.206 | 0.04 | VCAM antagonist | 0.04 0.027 DBMET00521 | DBMET00521 | |
| 0.025 | 0.211 | 0.191 | Protein kinase C alpha inhibitor | 0.191 0.006 DBMET00513 | DBMET00513 | |
| 0.013 | 0.203 | 0.039 | Delayed rectifier potassium channel blocker | 0.039 0.024 DBMET00513 | DBMET00513 | |
| 0.056 | 0.247 | 0.098 | CC chemokine 5 receptor agonist | 0.098 0.024 DBMET00513 | DBMET00513 | |
| 0.03 | 0.22 | 0.066 | Corticotropin releasing factor 2 receptor antagonist | 0.066 0.035 DBMET00513 | DBMET00513 | |
| 0.005 | 0.196 | 0.023 | Fructose-1,6-bisphosphatase 1 inhibitor | 0.023 0.018 DBMET00513 | DBMET00513 | |
| 0.004 | 0.196 | 0.019 | Integrin beta3 antagonist | 0.019 0.014 DBMET00521 | DBMET00521 | |
| 0.012 | 0.204 | 0.068 | NMDA 2C receptor antagonist | 0.058 0.047 DBMET00513 0.068 0.035 DBMET00521 | DBMET00521 | |
| 0.075 | 0.268 | 0.208 | DNA repair enzyme inhibitor | 0.208 0.008 DBMET00513 0.107 0.103 DBMET00521 | DBMET00513 | |
| 0.005 | 0.198 | 0.023 | Vitronectin receptor antagonist | 0.023 0.013 DBMET00521 | DBMET00521 | |
| 0.006 | 0.201 | 0.039 | Nicotinic alpha3beta4 receptor agonist | 0.039 0.011 DBMET00513 | DBMET00513 | |
| 0.004 | 0.199 | 0.017 | Alpha 2a adrenoreceptor agonist | 0.017 0.013 DBMET00513 | DBMET00513 | |
| 0.023 | 0.219 | 0.042 | CF transmembrane conductance regulator antagonist | 0.042 0.021 DBMET00513 | DBMET00513 | |
| 0.073 | 0.269 | 0.181 | Platelet adhesion inhibitor | 0.181 0.082 DBMET00521 | DBMET00521 | |
| 0.034 | 0.235 | 0.115 | Urease inhibitor | 0.115 0.05 DBMET00513 | DBMET00513 | |
| 0.017 | 0.22 | 0.063 | Cyclin-dependent kinase 6 inhibitor | 0.063 0.037 DBMET00513 | DBMET00513 | |
| 0.009 | 0.213 | 0.051 | CC chemokine 3 receptor antagonist | 0.051 0.024 DBMET00513 | DBMET00513 | |
| 0.014 | 0.219 | 0.036 | Erythropoietin receptor agonist | 0.036 0.033 DBMET00521 | DBMET00521 | |
| 0.067 | 0.274 | 0.139 | Hexokinase inhibitor | 0.139 0.092 DBMET00513 | DBMET00513 | |
| 0.048 | 0.258 | 0.174 | Nav1.4 sodium channel blocker | 0.174 0.025 DBMET00521 | DBMET00521 | |
| 0.005 | 0.216 | 0.031 | Endothelial nitric-oxide synthase inhibitor | 0.031 0.021 DBMET00513 | DBMET00513 | |
| 0.016 | 0.23 | 0.045 | Benzodiazepine antagonist | 0.045 0.038 DBMET00513 | DBMET00513 | |
| 0.039 | 0.256 | 0.13 | Interleukin 1 beta converting enzyme inhibitor | 0.13 0.028 DBMET00521 | DBMET00521 | |
| 0.009 | 0.226 | 0.03 | 5 Hydroxytryptamine 6 agonist | 0.03 0.017 DBMET00513 | DBMET00513 | |
| 0.018 | 0.236 | 0.077 | Amidase inhibitor | 0.077 0.04 DBMET00521 | DBMET00521 | |
| 0.025 | 0.253 | 0.078 | Potassium channel intermediate-conductance Ca-activated blocker | 0.078 0.019 DBMET00513 | DBMET00513 | |
| 0.012 | 0.242 | 0.03 | Complement factor 1s inhibitor | 0.03 0.008 DBMET00513 | DBMET00513 | |
| 0.033 | 0.266 | 0.061 | Histone deacetylase SIRT3 inhibitor | 0.061 0.046 DBMET00513 | DBMET00513 | |
| 0.008 | 0.245 | 0.088 | Glutamate (mGluR1) antagonist | 0.088 0.02 DBMET00513 | DBMET00513 | |
| 0.036 | 0.279 | 0.075 | Transcription factor RelA inhibitor | 0.075 0.023 DBMET00513 | DBMET00513 | |
| 0.021 | 0.266 | 0.044 | Integrin alpha1beta1 antagonist | 0.044 0.014 DBMET00521 | DBMET00521 | |
| 0.005 | 0.251 | 0.038 | Vascular adhesion protein 1 inhibitor | 0.038 0.029 DBMET00513 | DBMET00513 | |
| 0.035 | 0.285 | 0.166 | 5 Hydroxytryptamine 3A agonist | 0.166 0.028 DBMET00513 | DBMET00513 | |
| 0.022 | 0.274 | 0.054 | Fatty acid synthase inhibitor | 0.054 0.045 DBMET00513 | DBMET00513 | |
| 0.016 | 0.271 | 0.11 | Nicotinic alpha4beta2 receptor antagonist | 0.11 0.024 DBMET00513 | DBMET00513 | |
| 0.013 | 0.269 | 0.027 | Glucosylceramidase stimulant | 0.027 0.018 DBMET00513 | DBMET00513 | |
| 0.03 | 0.286 | 0.977 | DNA intercalator | 0.977 0.001 DBMET00513 0.09 0.086 DBMET00521 | DBMET00513 | |
| 0.071 | 0.331 | 0.148 | Pregnane X receptor agonist | 0.148 0.056 DBMET00513 | DBMET00513 | |
| 0.02 | 0.285 | 0.038 | Glucagon-like peptide 1 receptor antagonist | 0.038 0.033 DBMET00521 | DBMET00521 | |
| 0.005 | 0.271 | 0.02 | Imidazoline I1 receptor antagonist | 0.02 0.015 DBMET00513 | DBMET00513 | |
| 0.028 | 0.303 | 0.079 | Caspase 7 inhibitor | 0.079 0.062 DBMET00513 | DBMET00513 | |
| 0.005 | 0.283 | 0.036 | Potassium channel small-conductance Ca-activated activator | 0.036 0.018 DBMET00513 | DBMET00513 | |
| 0.017 | 0.297 | 0.043 | CC chemokine 4 receptor antagonist | 0.043 0.04 DBMET00513 | DBMET00513 | |
| 0.019 | 0.3 | 0.056 | 5 Hydroxytryptamine 7 agonist | 0.056 0.039 DBMET00513 | DBMET00513 | |
| 0.02 | 0.303 | 0.185 | Analgesic, opioid | 0.185 0.01 DBMET00513 | DBMET00513 | |
| 0.064 | 0.356 | 0.188 | 3C-like protease (Human coronavirus) inhibitor | 0.188 0.059 DBMET00513 | DBMET00513 | |
| 0.031 | 0.328 | 0.108 | Cell adhesion molecule inhibitor | 0.108 0.03 DBMET00521 | DBMET00521 | |
| 0.019 | 0.317 | 0.168 | Butyrylcholinesterase inhibitor | 0.168 0.028 DBMET00521 | DBMET00521 | |
| 0.025 | 0.324 | 0.079 | Myeloperoxidase inhibitor | 0.079 0.069 DBMET00513 | DBMET00513 | |
| 0.034 | 0.333 | 0.136 | Nav1.6 sodium channel blocker | 0.136 0.072 DBMET00513 | DBMET00513 | |
| 0.016 | 0.318 | 0.053 | Potassium channel (ATP-sensitive) activator | 0.053 0.024 DBMET00513 | DBMET00513 | |
| 0.067 | 0.368 | 0.278 | 5 Hydroxytryptamine 1E antagonist | 0.278 0.047 DBMET00513 | DBMET00513 | |
| 0.017 | 0.322 | 0.056 | Potassium channel (Inward rectifier) activator | 0.056 0.025 DBMET00513 | DBMET00513 | |
| 0.015 | 0.322 | 0.047 | Histamine H4 receptor antagonist | 0.047 0.036 DBMET00513 | DBMET00513 | |
| 0.004 | 0.314 | 0.025 | Prostaglandin D2 antagonist | 0.025 0.014 DBMET00521 | DBMET00521 | |
| 0.008 | 0.322 | 0.071 | Prostaglandin antagonist | 0.071 0.026 DBMET00521 | DBMET00521 | |
| 0.043 | 0.362 | 0.155 | MAP kinase kinase 2 inhibitor | 0.155 0.117 DBMET00513 | DBMET00513 | |
| 0.015 | 0.334 | 0.039 | Potassium channel Kv1.1 blocker | 0.039 0.025 DBMET00513 | DBMET00513 | |
| 0.03 | 0.359 | 0.212 | Thrombolytic | 0.212 0.046 DBMET00521 | DBMET00521 | |
| 0.02 | 0.353 | 0.061 | Aryl hydrocarbon receptor antagonist | 0.061 0.051 DBMET00513 | DBMET00513 | |
| 0.05 | 0.384 | 0.122 | Transcription factor STAT6 inhibitor | 0.122 0.056 DBMET00513 | DBMET00513 | |
| 0.03 | 0.364 | 0.094 | GABA receptor agonist | 0.094 0.084 DBMET00513 | DBMET00513 | |
| 0.029 | 0.376 | 0.09 | Beta glucuronidase inhibitor | 0.09 0.088 DBMET00513 | DBMET00513 | |
| 0.015 | 0.363 | 0.079 | Inducible nitric-oxide synthase inhibitor | 0.079 0.064 DBMET00513 | DBMET00513 | |
| 0.013 | 0.363 | 0.042 | ATR kinase inhibitor | 0.042 0.011 DBMET00513 | DBMET00513 | |
| 0.023 | 0.377 | 0.099 | Nitric-oxide synthase inhibitor | 0.099 0.062 DBMET00513 | DBMET00513 | |
| 0.015 | 0.37 | 0.056 | Cyclin D1 inhibitor | 0.056 0.05 DBMET00513 | DBMET00513 | |
| 0.002 | 0.359 | 0.008 | Free fatty acid receptor 2 antagonist | 0.008 0.006 DBMET00521 | DBMET00521 | |
| 0.02 | 0.386 | 0.06 | Phosphodiesterase 1A inhibitor | 0.06 0.042 DBMET00513 | DBMET00513 | |
| 0.063 | 0.43 | 0.178 | Transcription factor STAT3 inhibitor | 0.178 0.168 DBMET00513 | DBMET00513 | |
| 0.037 | 0.405 | 0.181 | Heat shock protein 90 antagonist | 0.181 0.048 DBMET00513 | DBMET00513 | |
| 0.036 | 0.406 | 0.153 | Cell adhesion inhibitor | 0.153 0.045 DBMET00521 | DBMET00521 | |
| 0.027 | 0.399 | 0.115 | Alpha 2b adrenoreceptor antagonist | 0.115 0.062 DBMET00513 | DBMET00513 | |
| 0.031 | 0.408 | 0.171 | I kappa B kinase epsilon inhibitor | 0.171 0.098 DBMET00513 | DBMET00513 | |
| 0.021 | 0.398 | 0.091 | Polo-like kinase-1 inhibitor | 0.091 0.059 DBMET00513 | DBMET00513 | |
| 0.036 | 0.414 | 0.111 | NADPH oxidase inhibitor | 0.111 0.095 DBMET00513 | DBMET00513 | |
| 0.021 | 0.4 | 0.53 | Topoisomerase II inhibitor | 0.53 0.006 DBMET00513 | DBMET00513 | |
| 0.035 | 0.414 | 0.177 | Amyloid beta aggregation inhibitor | 0.177 0.091 DBMET00521 | DBMET00521 | |
| 0.024 | 0.406 | 0.096 | Alpha 2c adrenoreceptor antagonist | 0.096 0.069 DBMET00513 | DBMET00513 | |
| 0.054 | 0.438 | 0.131 | MAP kinase 3 inhibitor | 0.131 0.104 DBMET00513 | DBMET00513 | |
| 0.058 | 0.467 | 0.258 | 15-Lipoxygenase inhibitor | 0.258 0.158 DBMET00521 | DBMET00521 | |
| 0.008 | 0.425 | 0.066 | Benzodiazepine agonist | 0.066 0.056 DBMET00513 | DBMET00513 | |
| 0.009 | 0.431 | 0.051 | Plasminogen activator inhibitor antagonist | 0.051 0.031 DBMET00521 | DBMET00521 | |
| 0.019 | 0.445 | 0.132 | Toll-Like receptor 9 antagonist | 0.132 0.076 DBMET00513 | DBMET00513 | |
| 0.005 | 0.456 | 0.626 | 5 Hydroxytryptamine uptake inhibitor | 0.626 0.004 DBMET00513 | DBMET00513 | |
| 0.008 | 0.462 | 0.055 | Alpha 2 adrenoreceptor agonist | 0.055 0.049 DBMET00513 | DBMET00513 | |
| 0.029 | 0.492 | 0.128 | Cyclin-dependent kinase 8 inhibitor | 0.128 0.106 DBMET00513 | DBMET00513 | |
| 0.067 | 0.536 | 0.844 | Analgesic | 0.844 0.005 DBMET00513 | DBMET00513 | |
| 0.029 | 0.502 | 0.164 | Calpain inhibitor | 0.164 0.157 DBMET00513 | DBMET00513 | |
| 0.022 | 0.522 | 0.179 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.179 0.114 DBMET00513 | DBMET00513 | |
| 0.024 | 0.531 | 0.506 | Antimitotic | 0.506 0.012 DBMET00513 | DBMET00513 | |
| 0.019 | 0.545 | 0.193 | Anticoagulant | 0.193 0.056 DBMET00521 | DBMET00521 | |
| 0.014 | 0.542 | 0.157 | Aryl hydrocarbon receptor agonist | 0.157 0.13 DBMET00513 | DBMET00513 | |
| 0.038 | 0.568 | 0.385 | Hypoxia-inducible factor 1 alpha inhibitor | 0.385 0.034 DBMET00513 | DBMET00513 | |
| 0.031 | 0.574 | 0.152 | Focal adhesion kinase 2 inhibitor | 0.152 0.127 DBMET00513 | DBMET00513 | |
| 0.029 | 0.631 | 0.166 | Histone acetyltransferase inhibitor | 0.166 0.118 DBMET00513 | DBMET00513 | |
| 0.016 | 0.623 | 0.192 | Estrogen antagonist | 0.192 0.014 DBMET00513 | DBMET00513 | |
| 0.004 | 0.633 | 0.149 | Neurokinin 1 antagonist | 0.149 0.005 DBMET00513 | DBMET00513 | |
| 0.049 | 0.681 | 0.202 | Catenin beta inhibitor | 0.202 0.03 DBMET00521 | DBMET00521 | |
| 0.013 | 0.646 | 0.082 | Factor XII inhibitor | 0.082 0.063 DBMET00521 | DBMET00521 | |
| 0.019 | 0.659 | 0.331 | Gonadotropin-releasing hormone receptor agonist | 0.331 0.003 DBMET00513 | DBMET00513 | |
| 0.004 | 0.661 | 0.304 | Substance P antagonist | 0.304 0.004 DBMET00513 | DBMET00513 | |
| 0.012 | 0.679 | 0.122 | Histone deacetylase class III inhibitor | 0.122 0.068 DBMET00521 | DBMET00521 | |
| 0.018 | 0.705 | 0.109 | Histone deacetylase SIRT1 inhibitor | 0.109 0.106 DBMET00521 | DBMET00521 | |
| 0.004 | 0.708 | 0.113 | Neurokinin antagonist | 0.113 0.009 DBMET00513 | DBMET00513 | |
| 0.012 | 0.814 | 0.088 | Thioredoxin inhibitor | 0.088 0.065 DBMET00521 | DBMET00521 | |
| 0.003 | 0.856 | 0.435 | Kinesin-like protein 1 inhibitor | 0.435 0.002 DBMET00513 | DBMET00513 | |
| 0.003 | 0.856 | 0.435 | Kinesin antagonist | 0.435 0.002 DBMET00513 | DBMET00513 | |
| 0.021 | 0.92 | 0.168 | Transforming growth factor beta 3 antagonist | 0.168 0.004 DBMET00513 | DBMET00513 | |
| 0.006 | 0.914 | 0.298 | ATM kinase inhibitor | 0.298 0.002 DBMET00513 | DBMET00513 | |
| 0.005 | 0.917 | 0.07 | Transcription factor AP-1 inhibitor | 0.07 0.03 DBMET00513 | DBMET00513 | |
| 0.004 | 0.927 | 0.548 | HERG channel blocker | 0.548 0.011 DBMET00513 | DBMET00513 | |
| 0.004 | 0.937 | 0.411 | Potassium channel (Voltage-sensitive) blocker | 0.411 0.025 DBMET00513 | DBMET00513 | |
| 0.003 | 0.941 | 0.13 | Epidermal growth factor antagonist | 0.13 0.029 DBMET00513 | DBMET00513 | |
| 0.004 | 0.943 | 0.148 | Potassium channel blocker | 0.148 0.137 DBMET00513 | DBMET00513 | |
| 0.004 | 0.955 | 0.137 | Epidermal growth factor receptor kinase inhibitor | 0.137 0.058 DBMET00513 | DBMET00513 | |
| 0.004 | 0.966 | 0.199 | DNA directed RNA polymerase inhibitor | 0.199 0.014 DBMET00513 | DBMET00513 | |
| 0.003 | 0.966 | 0.516 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | 0.516 0.004 DBMET00513 | DBMET00513 | |
| 0.003 | 0.966 | 0.496 | Check point kinase 1 inhibitor | 0.496 0.004 DBMET00513 | DBMET00513 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |